Apoptosis

Apoptosis is an autonomous, genetically controlled, orderly death of cells to maintain the stability of the internal environment. Unlike necrosis, apoptosis is not a passive process, but an active one, involving the activation, expression and regulation of a series of genes, and it is not a phenomenon of autologous damage under pathological conditions, but an active death process for better adaptation to the survival environment. Apoptosis is a fundamental biological phenomenon of cells and plays a necessary role in the removal of unwanted or abnormal cells in multicellular organisms. It plays an important role in the evolution of organisms, the stability of the internal environment, and the development of several systems. Apoptosis is not only a specific type of cell death, but also has important biological significance and complex molecular biological mechanisms.

Cat. No.	Product name
BP10580	Omaveloxolone
BP10580	Omaveloxolone (RTA-408) is a synthetic triterpenoid that activates the cytoprotective transcription factor Nrf2 and inhibits NF-κB signaling. Phase 2.
BP10476	ON 146040
BP10476	ON 146040 is an effective inhibitor of PI3K isoforms with IC50s of 14 and 20 nM for PI3Kα and PI3Kδ, respectively.
BP10360	ON1231320
BP10360	ON1231320 is a Polo-like kinase 2 (PLK2) inhibitor.
BP10414	ON123300
BP10414	ON123300 is a potent and multi-targeted kinase inhibitor for CDK4/Ark5/PDGFRβ/FGFR1/RET/Fyn (IC50: 3.9/5/26/26/9.2/11 nM).
BP10265	Onatasertib
BP10265	CC-223 is an orally available mTOR inhibitor with potential antitumor activity. CC-223 inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. CC-223 is a potent mTOR kinase inhibitor (IC50: 16 nM), with >150-fold sensitivity than the related lipid kinase PI3Kα (IC50: 4 μM).
BP10806	ONC212
BP10806	ONC212, a fluorinated-ONC201 analogue, is a selective agonist of GPR132.
BP10404	ONO-4059 analog
BP10404	ONO-4059 analogue is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.
BP10056	Onvansertib
BP10056	NMS-P937 (NMS1286937), an oral, specific Polo-like Kinase 1 (PLK1) inhibitor, is with IC50 of 2 nM. The specificity of NMS-P937 forPLK1 is 5000-fold higher over PLK2/PLK3.
BP10716	Orelabrutinib
BP10716	Orelabrutinib is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).
BP10936	Oritinib
BP10936	Oritinib is an inhibitor of EGFR with IC50s of 18, 0.7, 4, 0.1, 1.4 and 0.89 nM for EGFR (wt), EGFR (L858R), EGFR (L861Q), EGFR (L858R/T790M), EGFR (d746-750), EGFR (d746-750/T790M), respectively. Oritinib can be used in studies about the treatment of non-small cell lung cancer.
BP10173	Oroxin B
BP10173	Oroxin B has antioxidant activity.
BP10496	Osimertinib
BP10496	Osimertinib is a small molecule tyrosine kinase receptor inhibitor and antineoplastic agent that is used in the therapy of selected forms of advanced non-small cell lung cancer (NSCLC).
BP10957	Osimertinib dimesylate
BP10957	Osimertinib dimesylate is an irreversible and mutant selective EGFR inhibitor (IC50s: 12 and 1 nM against EGFR L858R and EGFR L858R/T790M).
BP10497	Osimertinib mesylate
BP10497	Osimertinib (AZD-9291) is an irreversible and mutant selective EGFR inhibitor (IC50s: 12/1 nM for EGFR(L858R) and EGFR(L858R/T790M)).
BP10959	OSU-T315
BP10959	OSU-T315 (1,5-regioisomer) is a ILK inhibitor.
BP10260	Otenaproxesul
BP10260	ATB-346 is a novel hydrogen sulphide-releasing derivative of naproxen with markedly reduced toxicity.
BP10390	OTS514
BP10390	OTS514 is a potent TOPK inhibitor. OTS514 exhibits a growth-suppressive effect on small cell lung cancer. OTS514 effectively suppressed the growth of SCLC cell lines (IC50: 0.4 ~ 42.6 nM). Treatment with OTS514 suppressed forkhead box protein M1 (FOXM1) activity. OTS514 treatment reduced CD90-positive SCLC cells and showed a higher cytotoxic effect against lung sphere-derived CSC-like SCLC cells.
BP10391	OTS964 hydrochloride
BP10391	OTS964 is a potent and selective TOPK inhibitor with potential anticancer activity.
BP10950	Oxibendazole
BP10950	Oxibendazole is a benzimidazole drug that interferes with metabolic pathways, used to protect against roundworms, strongyles, threadworms, pinworms and lungworm infestations in horses and some domestic pets.
BP10367	Oxybenzone
BP10367	Oxybenzone is an organic compound used in sunscreens. It is a derivative of benzophenone.